Pharmacological attenuation of apoptosis in reoxygenated endothelial cells.

Article Details

Citation
Copy to clipboard

Kabakov AE, Budagova KR, Malyutina YV, Latchman DS, Csermely P

Pharmacological attenuation of apoptosis in reoxygenated endothelial cells.

Cell Mol Life Sci. 2004 Dec;61(24):3076-86.

PubMed ID
15583868 [ View in PubMed
]
Abstract

BRX-235 (Iroxanadine), a novel drug developed by Biorex (Hungary), was previously characterized as a vasculoprotector against atherosclerosis, an activator of p38 kinase, and an enhancer of stress-responsive heat shock protein (Hsp) expression. The present data demonstrate that BRX-235 may improve survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. Addition of BRX-235 (0.1-1 microM) to culture medium prior to hypoxia or at start of reoxygenation significantly reduced the caspase-dependent apoptosis. The cytoprotection conferred by the pre-hypoxic drug administration was sensitive to quercetin and seems to be based on enhanced Hsp accumulation in stressed ECs. In the case of post-hypoxic drug administration, the cytoprotection was strongly inhibited by SB202190 and SB203580 and appears to be associated with enhanced p38 kinase activation in reoxygenated ECs.

DrugBank Data that Cites this Article

Drugs